A phase II study in 586 patients with albuminuric CKD has shown that 10 mg of vicadrostat (BI690517) [43], another aldosterone synthase inhibitor, reduced UACR by 40% compared with placebo, with or without associated empagliflozin treatment. The gene discussed is CYP11B2; the disease is chronic kidney disease.